Pharmacopeia Initiates Phase 2 Hypertension Study With PS433540 (DARA)
Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced the initiation of a Phase 2a clinical study of PS433540, the company’s lead internal product candidate. PS433540 is a dual-acting angiotensin and endothelin receptor antagonist (DARA) that is being developed as a potential treatment for hypertension and diabetic nephropathy.
